ClinicalTrials.gg
CompletedNCT06899490ML_AcuTongueUpdated Oct 21, 2026

"Machine Learning Analysis of Lingual Colorimetry and MADRS Anxiety-Depression Score in Acupuncture Patients"

An observational study in Anxiety Disorders, sponsored by Dr Benoit Bataille. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Dr Benoit Bataille · Observational

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
466
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 309 studies in Anxiety Disorders with a site in France — 74 open to participants now, 78 under way, 1 of them phase 3. Anxiety Disorders · France.

Enrollment
30th of 105
466 · median 150
Started
2024
with 15 others
Observational
105 of 309
21 open now
Registered
261st of 309
by date

Among the 309 studies in Anxiety Disorders with a site in France, this one is the 30th largest by enrollment of the 105 observational ones that give a count, is one of 16 that started in 2024, is one of 105 observational ones, and was the 261st registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

74 of the 309 studies in Anxiety Disorders with a site in France are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Anxiety Disorders with a site in France, or all of them as a file.
02

Study summary

This observational study aims to assess the potential relationship between tongue colorimetry (using standardized photographic techniques) and anxiety-depression scores measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) in acupuncture patients. Data will be analyzed using machine learning methods to determine whether tongue color features correlate with MADRS scores, possibly contributing to a novel, non-invasive diagnostic tool for anxiety and depression assessment in clinical practice.

Participation involves only tongue photography and completion of questionnaires, without any invasive procedures or treatment modifications.

Read the detailed description

This prospective observational study investigates the correlation between lingual colorimetry, captured using readily available and standardized modern photographic tools (iPhone cameras), and anxiety-depression scores evaluated by the Montgomery-Åsberg Depression Rating Scale (MADRS) among patients attending routine acupuncture consultations.

Participants will undergo a simple and non-invasive photographic recording of their tongue using an iPhone, ensuring consistent lighting and standardized positioning to minimize variability. Simultaneously, participants will complete the MADRS questionnaire, a widely validated instrument for assessing anxiety and depression severity. No invasive procedures or therapeutic interventions beyond their usual acupuncture care will be performed.

The acquired photographic data will be analyzed using machine learning algorithms to identify potential predictive relationships between distinct colorimetric characteristics of the tongue and the MADRS scores. The objective is to determine whether lingual imaging could serve as a reliable, non-invasive biomarker or complementary diagnostic tool for assessing psychological status in clinical practice.

This approach leverages everyday technology (smartphones), promoting ease of replication and broader accessibility in clinical environments. Ultimately, findings from this study could facilitate early detection and monitoring of anxiety-depressive disorders, thus enhancing individualized patient care in complementary and integrative medicine.

03

Conditions studied

  • Anxiety Disorders

Keywords

  • Tongue Colorimetry
  • MADRS
  • Depression
  • Anxiety
  • Machine Learning
  • Acupuncture
  • Artificial Intelligence
  • Image Analysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a prospective observational monocentric study conducted in an acupuncture practice. The study aims to establish a correlation between tongue colorimetric features and MADRS scores in patients consulting for symptoms related to anxiety.

Tongue photography and MADRS assessment present no risk to participants. A non-opposition declaration for photography and consent for anonymous and confidential data analysis will be obtained.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older
  • Native French speakers
  • No medical conditions or medications affecting tongue coloration
  • Consulting for acupuncture with symptoms involving an anxious component

Exclusion criteria

Exclusion Criteria:

  • Presence of psychosis or substance abuse
  • Eating or taking medication within one hour before the examination
  • Refusal to complete the Montgomery-Åsberg Depression Rating Scale (MADRS) questionnaire
  • Refusal to have their tongue photographed
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
466 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Correlation using Machine Learning between Tongue Colorimetric Features and MADRS Scores

    This study aims to evaluate the correlation between standardized tongue colorimetric parameters (obtained through digital photographs) and depression/anxiety scores measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Machine learning methods will be used to analyze tongue images and identify potential associations between colorimetric features and MADRS scores. Participants will be categorized into two subgroups: MADRS \< 15 and MADRS ≥ 15, to assess the ability of tongue characteristics to differentiate depression severity.

    Time frame: Baseline (single evaluation at enrollment)

Secondary outcomes

  1. Machine Learning Analysis of Tongue Features and MADRS Scores

    * Density Diagram. * Partial Correlation Analysis (Train/Test Split): Relationship between tongue color and MADRS scores. * Logistic Regression Model (Train/Test) * Support Vector Machine (SVM) on PCA: Model performance evaluation with ROC analysis. * Deep Learning Model: CNN applied to tongue images, classification based on color and texture. * Shapley Values Interpretation: Feature importance analysis for AI models. * Correlation Between Individual MADRS Items and Tongue Zones: Zone-by-zone statistical analysis. * MANCOVA Analysis: Multivariate analysis of covariance to assess multiple dependent variables. * CNN-based Model on Images: Direct classification of tongue features using convolutional neural networks. * Subgroup Identification via PCA (3 Components): Exploring potential depression subtypes.

    Time frame: Baseline (single evaluation at enrollment)

07

Study locations

1 site
  • Cabinet Médical d'Acupuncture
    Narbonne, 11100, France
08

References and documents

Individual participant data

Plan to share: Undecided — The potential sharing of IPD is currently undecided due to ethical considerations regarding the anonymization of tongue photographs. The ethics committee has highlighted the importance of ensuring that no identifiable characteristics can be traced back to participants. If a sharing plan is implemented, it will ensure strict anonymization protocols, including removing metadata, blurring any identifiable features, and restricting access to approved researchers under a confidentiality agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2025, 16 months.

Of 413 non-industry observational studies under Anxiety Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 49. This study's 16 months is below that.

Counting every sponsor, half of 441 studies reached it within 19 months; a quarter within 6 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2025 → Nov 2025 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 28, 2025
StartActual
Jun 27, 2024
Primary completionActual
Nov 1, 2025was Dec 2025
CompletionActual
Oct 1, 2026was Jun 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Primary completion
Dec 31, 2025→Nov 1, 2025 (actual)
Oct 21, 2026
Study completion
Jun 2026→Oct 1, 2026 (actual)
Oct 21, 2026
Enrollment
350 (estimated)→466 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Nov 1, 2025 (now actual)
    Study completion Jun 2026→Oct 1, 2026 (now actual)
    Enrollment 350 (estimated)→466 (actual)
    + 6 other changes: index terms, identifiers, verification date, oversight details, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06899490
Lead sponsor
Dr Benoit Bataille
Responsible party
Dr Benoit Bataille (MD, Centre Hospitalier de Narbonne) — Sponsor-investigator
First posted
Mar 28, 2025
Start date
Jun 27, 2024
Primary completion
Nov 1, 2025
Completion
Oct 1, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion